Funding Gap For Life Science Cos. Is Still A Problem
September 5, 2013, 12:16 PM EDT
Law360, New York (September 5, 2013, 12:16 PM EDT) -- During the first half of 2013, midstage life sciences companies have seen more initial public offerings than any year since 2004. However, for startup life sciences companies, the capital markets are decidedly less optimistic. Before these young companies can take advantage of a hot IPO market, they must raise substantial sums of money for research and development, intellectual property protection and clinical trials.
In fact, the typical drug or device company completing a successful IPO in the first half of 2013 raised approximately $100 million through...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.